Treatment of papillomavirus infections

Details Treatment of papillomavirus infections Treatment of papillomavirus infections

2007-02-06

2007-02-06

Salimi, Ali R. (Department: 1648)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S091100, C435S069100

Reexamination Certificate

active

11079525

ABSTRACT:
This invention relates to treatment of papillomavirus infections. Primarily there is provided a method of treatment of an existing papillomavirus (PV) infection which includes the step of administration of PV VLPs selected from the group consisting of PV L1 VLPs and PV L1/L2 VLPs to a patient suffering from the PV infection. Suitably the PV infection is characterised by the presence of epithelial lesions. The major infection which is treated are gential warts caused by HPV 6 and HPV 11.

REFERENCES:
patent: 5437951 (1995-08-01), Lowy et al.
patent: 5716620 (1998-02-01), Lowy et al.
patent: 5744142 (1998-04-01), Lowy et al.
patent: 5821087 (1998-10-01), Lowe et al.
patent: 5888516 (1999-03-01), Jansen et al.
patent: 6436402 (2002-08-01), Zhao et al.
patent: WO 93/02184 (1993-02-01), None
patent: WO 96/15247 (1996-05-01), None
patent: WO 96/29413 (1996-09-01), None
patent: WO 96/30520 (1996-10-01), None
patent: WO 98/10790 (1998-03-01), None
patent: WO 98/15631 (1998-04-01), None
patent: WO 98/28003 (1998-07-01), None
patent: WO 98/44944 (1998-10-01), None
patent: WO 99/09177 (1999-04-01), None
patent: WO 99/18220 (1999-04-01), None
patent: WO 00/35478 (2000-06-01), None
Stanley,Expert Rev. Vaccine, Jun. 2003, pp. 381-389, vol. 2, No. 3.
Frazer,Virus Research, 2002, pp. 271-274, vol. 89.
Peng et al.,Pathology, 1999, pp. 418-422, vol. 31.
Barrasso, “Treatment of genital warts: an Overview,”J. Obstet. Gynecol., 1998, pp. S70-S71, vol. 18.
Bavinck, “HPV Infections and Immunosuppression,”Clin. Dermatol., 1997, pp. 427-437, vol. 15.
Bernard, “Evolution of Papillomaviruses,”Crr. Topics Microbiol. Immunol., 1994, pp. 34-51, vol. 186.
Beutner, “Therapeutic approaches to Genital Warts,”Am. J. Med., 1997, pp. 28-37, vol. 102.
Beutner, “Imiquimod, a Patient-Applied Immune-Response Modifier for Treatment of External Genital Warts,”Antimicrobial Agents and Chemotherapy, 1998, pp. 789-794, vol. 42.
Breitburd, “Immunization with Viruslike Particles from Cottontail Rabbit Papillomavirus (CRPV) Can Protect against Experimental CRPV Infection,”J. Virol., 1995, pp. 3959-3963, vol. 69.
Broker, “Structure and Genetic Expression of Papillomaviruses,”Obstect. Gynecol. Clin. N. Am., 1987, pp. 329-343, vol. 14.
Carter, “The Natural History of Human Papillomavirus Type 16 Capsid Antibodies among a Cohort of University Women,”Infec. Dis., 1996, pp. 927-936, vol. 174.
Coleman, “Immunological Events in Regressing Genital Warts,”Anat. Pathol., 1994, pp. 763-773, vol. 102.
Christensen, “Human Papillomaviruses Types 6 and 11 Have Antigenetically Distinct Strongly Immunogenic Conformationally Dependent Neutralizing Epitopes,”Virol., 1994, pp. 329-335, vol. 205.
De Bruijn, “L1 Specific Protection from Tumor Challenge Elicited by HPV16 Virus-like Particles,”Virol., 1998, pp. 371-376, vol. 250.
Christensen, “Immunization with Viruslike Particles Induces Long-Term Protection of Rabbits against Challenge with Cottontail Rabbit Papillomavirus,”J. Virol., 1996, pp. 960-965, vol. 70.
Dupuy, “Cell mediated immunity induced in mice by HPV16 L1 virus-like particles,”Microbial Pathogenesis, 1997, pp. 219-225, vol. 22.
Evander, “Identification of the α6integrin as a Candidate Receptor for Papillomavirus,”J. Virol., 1997, pp. 2449-2456, vol. 71.
Frazer, “Immunology of Papillomavirus infection,”Curr. Opin. Immunol., 1996, pp. 484-491, vol. 8.
Giri, “Papillomavirus genomes: from sequence data to biological properties,”TIG, 1986, pp. 227-232, vol. 2.
Greenstone, “Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in a HPV16 tumor model,”Proc. Natl. Acad. Sci., USA, 1998, pp. 1800-1805, vol. 95.
Hagenese, “Progress in the Development of HPV Vaccines,”Infect. Med., 1997, pp. 555-564, vol. 14.
Hines, “Prospects for Human Papillomavirus vaccine development: emerging HPV vaccines,”Curr. Opin. Inf. Dis., 1998, pp. 57-61, vol. 11.
Kirnbauer, “Efficient Self-Assembly of Human Papillomavirus Type 16 L1 and L1-L2 into Virus-like Particles,”J. Virol., 1993, pp. 6929-6936, vol. 67.
Park, “Human papillomavirus type 16, E6, E7 and L1 and type 18 proteins produced by recombinant baculovirus,”J. Virol. Meth., 1993, pp. 303-318.
Peng, “Papillomaviruse Virus-like Particles Can Deliver Defined CTL Epitopes to the MHC Class 1 Pathway,”Virol., 1998, pp. 147-157, vol. 240.
Price, “α6Integrins are required for Langerhams Cell Migration from the Epidermis,”J. Exp. Med., 1997, pp. 1725-1735, vol. 186.
Qi, “Epithelial Cells Display Separate Receptors for Papillomavirus VLPs and for Solubule L1 Capsid Protein,”Virol., 1996, pp. 35-45, vol. 216.
Rose, “Expression of Human Papillomavirus Tupe 1 1 L1 Protein in Insect Cells: In Vivo and In Vitro Assembly of Viruslike Particles,”J. Virol., 1993, pp. 1936-1944, vol. 67.
Rose, “Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles,”J. Gen. Virol., 1994, pp. 2445-2449, vol. 75.
Sasagawa, “Synthesis and Assembly of Virus-like Particles of Human Papillomavirus Type 6 and Type 16 in Fission Yeast Schizosaccharomyces pombe,”Virol., 1995, pp. 126-135, vol. 206.
Salzman et al., “Sequence Analysis of Papillomavirus Genomes,” in he Papovaviridiae: vol. 2, The Papillomavirus Plenum Press, 1987.
Schiller, “Papillomavirus-like Particles,”Papillomavirus Report, 1995, pp. 121-128, vol. 6.
Schirmbeck, “Virus-like Particles Induce MHC Class I-Restricted T Cell Responses,”Intervirol. 1996, pp. 111-119, vol. 39.
Sing, “Isolation of Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes that Lyse Reed-Sternberg Cells: Implications for Immune-Mediated Therapy of EBV+ Hodgkin's Disease,”Blood, 1997, pp. 1978-1986, vol. 89.
Sokolowski, “mRNA Instability Elements in the Human Papillomavirus Type 16 L2 Coding Region,”J. Virol., 1998, pp. 1504-1515, vol. 72.
Stuart-Harris, “Clinical Applications of the Interferons,”Chapman and Hall Medical, 1997.
Suzich, “Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas,”Proc. Natl. Acad. Sci. USA, 1995, pp. 11553-11557, vol. 92.
Walter, “Reconstruction of Cellular Immunity Against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor,”New England J. Med., 1995, pp. 1038-1044, vol. 333.
Yamada, “Human Papillomavirus Type 16 Variant Lineages in United States Populations Characterized by Nucleotide Sequence Analysis of the E6, L2 and L1 Coding Segments,”J. Virol., 1995, pp. 7743-7753, vol. 69.
Zhou, “Expression of Vaccinia Recombinant HPV 16 L1 and L2 ORF Proteins in Epithelial Cells is Sufficient for Assembly of HPV Virion-like Particles,”Virol., 1991, pp. 251-257.

Affiliated with

Also associated with

Rating

Treatment of papillomavirus infections does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of papillomavirus infections, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of papillomavirus infections will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3820425